Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

On Monday, Nanobiotix SA (NASDAQ:NBTX) announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company (NYSE:JNJ), as part of its financial strategy.

The revision relieves Nanobiotix of funding obligations for its pivotal NANORAY-312 Phase 3 trial while modifying certain future milestone payments.

The company expects the changes to bolster its financial stability and extend its cash runway.

Under the revised agreement, Johnson & Johnson will assume nearly all remaining costs for NANORAY-312 through trial completion, with Nanobiotix covering only a small portion.

Also Read: Asia And Europe Markets Gains, Gold Makes ...